← Evidence map

ArticleEBioMedicine2023

Corrigendum to "MeCP2 promotes gastric cancer progression through regulating FOXF1/Wnt5a/β-Catenin and MYOD1/Caspase-3 signaling pathways" [EBioMedicine 16 (2017) 87-100].

Lingyu Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Corrigendum to "MeCP2 promotes gastric cancer progression through regulating FOXF1/Wnt5a/β-Catenin and MYOD1/Caspase-3 signaling pathways" [EBioMedicine 16 (2017) 87-100]. | OpenQuestion